{"pair":{"gene":"CYP2C19","drug":"clopidogrel","guideline":"CPIC","level":"CPIC A","summary":"Prodrug activated by CYP2C19. CPIC 2022 recommends an alternative antiplatelet (prasugrel or ticagrelor) for poor and intermediate metabolizers undergoing PCI for acute coronary syndromes. FDA boxed warning about reduced effectiveness in poor metabolizers.","phenotypes":["Poor metabolizer (PM): two no-function alleles (e.g. *2/*2, *2/*3)","Intermediate metabolizer (IM): one no-function allele with one normal or increased-function allele (e.g. *1/*2, *2/*17)","Normal metabolizer (NM): two normal-function alleles (*1/*1)","Rapid metabolizer (RM): one normal and one increased-function allele (*1/*17)","Ultra-rapid metabolizer (UM): two increased-function alleles (*17/*17)"],"sources":[{"label":"CPIC — CYP2C19 gene page","url":"https://cpicpgx.org/gene/cyp2c19/"},{"label":"PharmGKB CYP2C19 (PA124)","url":"https://www.pharmgkb.org/gene/PA124"},{"label":"PharmVar CYP2C19","url":"https://www.pharmvar.org/gene/CYP2C19"},{"label":"Lee et al., Clin Pharmacol Ther 2022 (CPIC clopidogrel guideline update)","url":"https://pubmed.ncbi.nlm.nih.gov/35034351/"},{"label":"FDA label, Plavix (clopidogrel) (boxed warning on CYP2C19 poor metabolizers)","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de8b0b67-eb25-4684-83b5-7ad785314227"}]},"meta":{"disclaimer":"Educational information only, not medical advice or diagnosis. Consult a clinician before acting on genetic information.","api_version":"2026-09-20","docs":"https://deepdna.ai/docs/","status":"live","data_as_of":"2026-10-25T21:32:19.251Z","freshness":"https://deepdna.ai/api/v1/freshness"}}